ArticleSmart molecules : open access2025
A photoactivatable tumor-targeting in situ nanovaccine for large-volume tumor therapy.
Article in Smart molecules : open access, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Molecular Engineering Boosts Photon-Activated Immunotherapy for Prostate Cancer Through Concurrent Pyroptosis and cGAS-STING Pathway Activation.Angewandte Chemie (International ed. in English) · 2026Article
- Carrier-Free Nanoassembly Suppresses Phase Separation via Ribosome-Inspired Crowding Control for Enhanced Chemo-Immunotherapy.ACS nano · 2026Article
- Zero-trigger ultrafast charge-transfer J-aggregatesChemical science · 2026Article
- A photoactivatable tumor-targeting in situ nanovaccine for large-volume tumor therapy.Smart molecules : open access · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The clinical application of tumor vaccines is hindered by challenges such as time-consuming and costly production processes. In this context, in situ cancer vaccines represent a promising strategy by leveraging endogenous tumor antigens to elicit robust antitumor T cell responses. Herein, a photoactivatable tumor-targeting in situ nanovaccine, Lipo-D8-6, was constructed using cRGD-functionalized liposomes that co-encapsulated the photosensitizer chlorin e6 and a cleavable immunoadjuvant conjugate D8, allowing light-triggered synchronous activation of three therapeutic modules. Upon near-infrared light irradiation, Lipo-D8-6 generates reactive oxygen species that exert direct cytotoxicity on tumor cells and induce immunogenic cell death, while concurrently cleaving the responsive linker within D8 to achieve the controlled release of R848. In vivo biodistribution analysis confirmed the superior intratumoral accumulation of Lipo-D8-6, facilitating precise treatment. In a large-volume tumor model, the nanovaccine exhibited pronounced antitumor efficacy, accompanied by enhanced tumor infiltration of CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.